New Tysabri data from ECTRIMS

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

New Tysabri data from ECTRIMS

Postby MSUK » Thu Oct 03, 2013 1:15 am

New Tysabri data show earlier treatment & longer-term use result in significant reductions in MS disease activity

Biogen Idec announced results from several new analyses of Tysabri(R) (natalizumab) data that demonstrate its effectiveness in reducing multiple sclerosis (MS) disease activity. This effect was particularly significant in people with relapsing MS who initiated treatment when they had lower Expanded Disability Status Scale (EDSS) scores as well as in those who have been treated for more than two years. These data will be presented at the 29(th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark from 2-5 October....... Read More - http://www.ms-uk.org/tysabri
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2211
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Re: New Tysabri data from ECTRIMS

Postby HarryZ » Thu Oct 03, 2013 11:04 am

Well, I guess one can choose to believe what Biogen is telling us about Tysabri. Remember, this is the same company that once upon a time told us that Tysabri was totally safe to use with few side effects!

With over 400 cases of PML and thousands of MS patients reporting a ton of heavy duty side effects, I suppose it comes down to what kind of risk a MS patient is willing to take with long term use of the drug and how much they trust what Biogen tells us as being accurate. And we all remember the nice and convincing stats that were fed to us by the CRAB manufactures over the years!

Harry
User avatar
HarryZ
Family Elder
 
Posts: 2557
Joined: Tue May 25, 2004 2:00 pm
Location: London, ON, Canada


Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service